ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,296 GBX | -0.87% |
|
+1.54% | +16.00% |
| 02:06pm | Innate Pharma: five abstracts selected for ASCO | CF |
| 02:07am | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
170.1
USD
Spread / Average Target
+7.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.00% | 244B | |
| +38.87% | 728B | |
| +33.05% | 603B | |
| -5.78% | 360B | |
| +18.92% | 332B | |
| +1.13% | 279B | |
| +8.09% | 207B | |
| -5.77% | 205B | |
| +6.31% | 164B | |
| -0.27% | 122B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca CEO Rejects Media Claims of Departure Plans
